M.D., Ph.D.• Treatment and management of adult cancer patients, chemo-, targeted, immunotherapy of solid tumors (NSCLC, breast, GI, GU, melanoma), participating in weekly multidisciplinary tumor boards;• Interpretation and analysis of NGS (next-generation sequencing) to individually tailor cancer therapies.Industry experience:04-07.2021: research enablement platform “Guidepoint”, New York, USA (remote).• Advisor for design, feasibility, and conduct of 3 pre-clinical trials… Show more M.D., Ph.D.• Treatment and management of adult cancer patients, chemo-, targeted, immunotherapy of solid tumors (NSCLC, breast, GI, GU, melanoma), participating in weekly multidisciplinary tumor boards;• Interpretation and analysis of NGS (next-generation sequencing) to individually tailor cancer therapies.Industry experience:04-07.2021: research enablement platform “Guidepoint”, New York, USA (remote).• Advisor for design, feasibility, and conduct of 3 pre-clinical trials with pipeline development.• Provided scientific and clinical insights to optimize pre-clinical programs that decreased pre-clinical drug development timeline by 5%.Clinical trial experience: 2017 – now:●Phase II/III and EAP of Kymriah (CAR-T), Yescarta (CAR-T), alpelisib, nintedanib, olaparib, ribociclib, kadcyla, enhertu, pembrolizumab, nivolumab, ipilimumab in various indications (adult metastatic/advanced tumors), to accelerate access and delivery of life saving cancer treatments.●WO42178/ENGOT-GYN2/GOG-3051, a Phase II, multicenter, Study Evaluating the Efficacy and Safety of Biomarker-Driven Therapies in Patients With Persistent or Recurrent Rare Epithelial Ovarian Tumors: ipatasertib and paclitaxel, cobimetinib, trastuzumab emtansine, atezolizumab and bevacizumab, giredestrant and abemaciclib, inavolisib and palbociclib, letrozole, olaparib.Sub-investigator functionality:●Pre-selection of study participants, work with referrals●Consent and enrollment●Response assessment (RECIST)●Safety assessment and adverse events documentation (CTCAE)Leadership:- trained and mentored a team of 6 junior oncologists and nurses;- launched development of an inpatient unit for cancer patients;- led updating a hospital for a JCI audit (Joint Commission International);- raised cancer management standards: decreased treatment times from 3 to 2 weeks, improved consistent monitoring of patient’s response to therapy, with 69% of metastatic patients responding favorably to treatment. Show less

• as an Advisor, performed independent consults on innovative trends in oncology early drug development and translational oncology, provided scientific insights to optimize clinical programs that decreased pre-clinical drug development timeline by 15%.

• By leading a cross-functional clinical study team, I conducted a retrospective single-center clinical trial (n = 341) on clinical and molecularissues of hormonal therapy in breast cancer patients of young age (clinical study design, data collection, analysis, data interpretation).• Obtained an overall accuracy over 86% in patients with stages 1 - 3 of breast cancer, and identified molecular markers associated withhormonal therapy effectiveness, reaching statistical significance of… Show more • By leading a cross-functional clinical study team, I conducted a retrospective single-center clinical trial (n = 341) on clinical and molecularissues of hormonal therapy in breast cancer patients of young age (clinical study design, data collection, analysis, data interpretation).• Obtained an overall accuracy over 86% in patients with stages 1 - 3 of breast cancer, and identified molecular markers associated withhormonal therapy effectiveness, reaching statistical significance of p<0.05.• Consultant – Peccatori Fedro, M.D., Ph.D., Istituto Europeo di oncologia, Milano, Italia. Show less

oncology residency